Premium
Pharmacokinetic and pharmacodynamic variations of acenocoumarol orally administrated either once or twice daily in patients with deep venous thrombosis
Author(s) -
Mismetti P,
Reynaud J,
LaporteSimitsidis S,
Thijssen H,
TardyPoncet B,
Tardy B,
Buchmuller A,
Decousus H
Publication year - 1998
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1998.tb00997.x
Subject(s) - acenocoumarol , pharmacodynamics , pharmacokinetics , medicine , anticoagulant , anesthesia , thrombosis , deep vein , venous thrombosis , warfarin , atrial fibrillation
Summary— The literature suggests that variations in anticoagulant effect occur when acenocoumarol is administrated in a daily dose. We assessed the anticoagulant effects of acenocoumarol with INR, factors VII and X and protein C in 12 randomly selected hospitalised patients with deep‐vein thrombosis, six of them receiving a daily dose of acenocoumarol, the other six receiving twice‐daily doses. When the drug effect had been at a steady‐state for at least 72 h, five blood samples were drawn per patient over a period of 24 h. No nycthemeral significant variations were noted for INR, factor X and protein C in the two groups ( P > 0.10). Nycthemeral significant variation in factor VII when acenocoumarol was administered once daily was noted ( P = 0.02), but the clinical relevance of factor VII variation at steady‐state is uncertain. In spite of the short pharmacokinetic half‐life of acenocoumarol, a stable nycthemeral pharmacodynamic activity was observed after once daily administration; twice‐daily administration of acenocoumarol does not appear to be justified.